Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin

International Heart Journal

Volumn 52, Issue 1, 2011, Pages 44-49

  Miyagata, You ^a   Nakai, Kenji ^a   Sugiyama, Yoshiki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

CYP2C9; Genotype; Individual therapy; Japanese; VKORC1; Warfarin

Indexed keywords

ADENINE; CYTOCHROME P450 2C9; CYTOSINE; OXIDOREDUCTASE; PROTHROMBIN; THYMINE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; DRUG USE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ORAL SURGERY; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC MARKERS; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ORAL SURGICAL PROCEDURES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WARFARIN;

EID: 79951531419     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.44     Document Type: Article

References (33)

1. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-66.
2. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-9.
3. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
4. Berwaerts J, Dijkhuizen RS, Robb OJ, Webster J. Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage. Stroke 2000; 31: 2558-62.
5. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
6. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007; 63: 1135-41.
7. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
8. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
9. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
10. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
11. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet and Genomics 2006; 16: 101-10.
12. Ozer N, Cam N, Tangurek B, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels 2010; 25: 155-62.
13. Mushiroda T, Ohnishi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 2006; 51: 249-53.
14. *3 (IIe359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78: 107-11.
15. Nakai K, Tsuboi J, Okabayashi H, et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 2007; 8: 713-9.
16. Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45: 1334-40. (Review)
17. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
18. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
19. Rieder MJ, Reine AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
20. Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med & Res 2007; 5: 8-16.
21. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-30.
22. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P- 4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9.
23. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28.
24. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63. (Review)
25. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differenc es in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
26. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CKP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
27. Osman A, Enström C, Arbring K, Söderkvist P, Lindahl TL. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 2006; 4: 1723-9.
28. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter- ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
29. Matsuyama K, Matsumoto M, Sugita T, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002; 66: 668-70.
30. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-6. (Review)
31. Evans IL, Sayers MS, Gibbons AJ, Price G, Snooks H, Sugar AW. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. Br J Oral Maxillofac Surg 2002; 40: 248-52.
32. Todd DW. Anticoagulated patients and oral surgery. Arch Intern Med 2003; 163: 1242.
33. Bayne D, Brennan PA. Warfarin therapy adjustment for oral surgery is an unnecessary risk. Arch Intern Med 2008; 168: 1932.